Patient characteristics and sites of primary ocular involvement in OAML
Reference, year . | No. of patients . | Age, y . | Sex, M/F . | Orbit . | Conjunctiva . | Lacrimal . | Eyelid . | Bilateral, % . | Stage I, % . |
---|---|---|---|---|---|---|---|---|---|
Nakata et al,12 1999 | 35 | 59 | 23/12 | 9 | 71 | 20 | ND | ND | 91 |
Auw-Haedrich et al,45 2001 | 38 | 63 | 17/29 | 42 | 39 | 0 | 19 | 7 | 84 |
Mannami et al,15 2001 | 37 | 60 | 22/15 | 43 | 38 | 18 | 0 | 16 | 97 |
McKelvie et al,6 2001 | 44 | 65 | 16/28 | 48 | 27 | 18 | 7 | 13 | 91 |
Cho et al,11 2003 | 61 | 45 | 25/36 | 25 | 31 | 7 | 38 | 10 | 83 |
Hasegawa et al,46 2003 | 20 | 59 | 10/10 | 20 | 30 | ND | ND | ND | 95 |
Uno et al,47 2003 | 50 | 61 | 33/17 | 34 | 58 | 4 | 4 | 14 | 100 |
Coupland et al,7 2005 | 136 | 64 | 36/100 | 40 | 35 | 7 | 18 | 16 | 86 |
Lee et al,48 2005 | 37 | 44 | 22/15 | 29 | 51 | 11 | 8 | 18 | 74 |
Ben Simon et al,49 2006 | 33 | 72 | 14/19 | 30 | 21 | 24 | 18 | 12 | 100 |
Charlotte et al,50 2006 | 23 | 66 | 11/12 | 35 | 35 | 9 | 0 | 22 | 78 |
Ejima et al,51 2006 | 42 | 61 | 26/16 | 48 | 28 | 24 | 0 | 21 | 100 |
Rosado et al,42 2006 | 55 | 66 | 35/20 | 47 | 29 | 24 | 0 | 10 | 84 |
Suh et al,52 2006 | 48 | 47 | 30/18 | 54 | 31 | 0 | 15 | 15 | 96 |
Ferry et al,10 2007 | 182 | 65 | 75/107 | 47 | 33 | 16 | ND | 11 | 92 |
Song et al,53 2007 | 21 | 59 | 15/6 | 38 | 29 | 10 | 24 | 10 | 90 |
Tanimoto et al,54 2007 | 114 | 58 | 71/43 | 59 | 36 | 3 | 2 | 15 | 94 |
Yoon et al,17 2007 | 60 | 46 | 29/40 | 47 | 35 | 17 | 2 | 12 | 90 |
Reference, year . | No. of patients . | Age, y . | Sex, M/F . | Orbit . | Conjunctiva . | Lacrimal . | Eyelid . | Bilateral, % . | Stage I, % . |
---|---|---|---|---|---|---|---|---|---|
Nakata et al,12 1999 | 35 | 59 | 23/12 | 9 | 71 | 20 | ND | ND | 91 |
Auw-Haedrich et al,45 2001 | 38 | 63 | 17/29 | 42 | 39 | 0 | 19 | 7 | 84 |
Mannami et al,15 2001 | 37 | 60 | 22/15 | 43 | 38 | 18 | 0 | 16 | 97 |
McKelvie et al,6 2001 | 44 | 65 | 16/28 | 48 | 27 | 18 | 7 | 13 | 91 |
Cho et al,11 2003 | 61 | 45 | 25/36 | 25 | 31 | 7 | 38 | 10 | 83 |
Hasegawa et al,46 2003 | 20 | 59 | 10/10 | 20 | 30 | ND | ND | ND | 95 |
Uno et al,47 2003 | 50 | 61 | 33/17 | 34 | 58 | 4 | 4 | 14 | 100 |
Coupland et al,7 2005 | 136 | 64 | 36/100 | 40 | 35 | 7 | 18 | 16 | 86 |
Lee et al,48 2005 | 37 | 44 | 22/15 | 29 | 51 | 11 | 8 | 18 | 74 |
Ben Simon et al,49 2006 | 33 | 72 | 14/19 | 30 | 21 | 24 | 18 | 12 | 100 |
Charlotte et al,50 2006 | 23 | 66 | 11/12 | 35 | 35 | 9 | 0 | 22 | 78 |
Ejima et al,51 2006 | 42 | 61 | 26/16 | 48 | 28 | 24 | 0 | 21 | 100 |
Rosado et al,42 2006 | 55 | 66 | 35/20 | 47 | 29 | 24 | 0 | 10 | 84 |
Suh et al,52 2006 | 48 | 47 | 30/18 | 54 | 31 | 0 | 15 | 15 | 96 |
Ferry et al,10 2007 | 182 | 65 | 75/107 | 47 | 33 | 16 | ND | 11 | 92 |
Song et al,53 2007 | 21 | 59 | 15/6 | 38 | 29 | 10 | 24 | 10 | 90 |
Tanimoto et al,54 2007 | 114 | 58 | 71/43 | 59 | 36 | 3 | 2 | 15 | 94 |
Yoon et al,17 2007 | 60 | 46 | 29/40 | 47 | 35 | 17 | 2 | 12 | 90 |
ND indicates not determined.